OncoBay Clinical Aims to Accelerate Immuno-Oncology Research

OncoBay Clinical Aims to Accelerate Immuno-Oncology Research

New immunotherapy-focused contract research organization offers end-to-end services for pharmaceutical and biotech companies

TAMPA, Fla. (June XX, 2020) — Oncology research has experienced an expansive transformation from the therapies tested and delivered less than a decade ago to those delivered today. In 2019, more than 400 immunotherapy products were available to patients and over 400 more were in development. These innovative therapies change the way we treat and manage patients. At OncoBay Clinical we know that new treatments with added complexities and unique safety profiles require a new approach, not just a band-aid on old methods. Innovation requires innovation. Introducing OncoBay Clinical, the next generation of contract research organization (CRO) support.

OncoBay Clinical, is a first-of-its-kind immuno-oncology CRO specializing in rare and complex oncology indications including immunotherapies and cellular therapies. A boutique CRO, OncoBay Clinical is a wholly owned for-profit subsidiary of Moffit Cancer Center. As a National Cancer Institute-designated Comprehensive Cancer Center, Moffitt has been at the forefront of development and research. Through direct partnership, OncoBay Clinical now leverages the unrivaled support of Moffitt’s top scientific advisors imbedding scientific expertise into every project team and creating “vein to vein” control of cell therapy (CTx) trials including those focused on tumor infiltrating lymphocyte (TIL) and chimeric antigen receptor T-cell (CAR T) therapies.

“OncoBay is filling a much-needed space in the industry, innovating in a way that is unprecedented. Our model revolutionizes the approach to oncology clinical trials and has been designed and built based upon the most difficult trials as a framework, thus allowing us to succeed in managing the most complex programs.” said Krystyna Kowalczyk, president and CEO of OncoBay Clinical. “Through our partnership with Moffitt Cancer Center, OncoBay Clinical has the ability to integrate scientific expertise with operational excellence and manufacturing capabilities to provide full service, custom curated solutions for our clients.”

OncoBay Clinical is a full-service CRO offering end-to-end services for pharmaceutical and biotech companies. Specializing in immuno-oncology clinical trials, OncoBay Clinical boasts a respected team of executive leaders with more than 100 years of oncology operations experience, all of whom are personally dedicated to the success of immuno-oncology clinical trials from start to finish.

To learn more about OncoBay Clinical, please visit www.OncoBay.com.

About OncoBay Clinical
OncoBay Clinical is a boutique contract research organization (CRO) specializing in immuno-oncology/cell therapy, offering full- service custom-curated CRO solutions for global pharmaceutical and biotech companies looking to advance their immuno-oncology product or device. As a wholly owned, for-profit subsidiary of Moffitt Cancer Center, OncoBay embeds scientific expertise, operational excellence and integrated cell manufacturing capabilities providing true end-to-end control. Built on years of IO and cell therapy expertise, a streamlined technology framework, a highly trained site network, and a dedicated team of experienced professionals, OncoBay is committed to operational excellence from start to finish. For more information, visit Oncobay.com and follow us on Facebook, Twitter and LinkedIn.

About Moffitt Cancer Center

Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 51 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt is a Top 10 cancer hospital and has been nationally ranked by U.S. News & World Report since 1999. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 6,500 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.


Deborah Turunjian
OncoBay Clinical, Vice-President Business Operations

The Latest News & Events


Take Advantage of OncoBay’s Innovative Approach


Submit a Request for Proposal

Submit Proposal

OncoBay is now Kapadi


Once three entities – OncoBay Clinical, Clinscience, and Exom Group s.r.l – now we stand as one, bringing forth a symphony of expertise and seamless operations. To celebrate our unity, we re-brand under the banner of Kapadi, and embark on a new chapter of exceptional service in oncology clinical research.

Kapadi is not just a name; it's a testament to our fusion. It signifies the our standing as a global CRO powerhouse committed to accelerating groundbreaking cancer therapies that uplift patients worldwide. From conceptualizing studies, navigating regulations, and analyzing data, we provide a comprehensive array of services designed to empower your oncology clinical trials.


Visit Kapadi.com


This pop-up will auto-close in 10 seconds.

This will close in 5 seconds